Enochian Biosciences Inc.
| NASDAQ: ENOB | Healthcare / Biotechnology / USA |
| 0.7967 | -0.0733 | -8.42% | Vol 1.30M | 1Y Perf -75.52% |
| Aug 7th, 2023 09:39 DELAYED |
| BID | 0.7901 | ASK | 0.8199 | ||
| Open | 0.8700 | Previous Close | 0.00 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | Neutral | |
| Market Cap | 46.44M | Earnings Date | 11th Aug 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.22 | |
| Beta | 0.94 |
Today's Price Range 0.78000.8700 | 52W Range 0.39282.99 | 5 Year PE Ratio Range -13.50-16.70 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | 1.08% | ||
| 1 Year | -75.52% | ||
| 3 Years | -73.17% | ||
| 5 Years | -89.72% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -9.50 | |||
ROE last 12 Months | -25.79 | |||
ROA (5Y Avg) | -6.25 | |||
ROA last 12 Months | -23.57 | |||
ROC (5Y Avg) | -38.44 | |||
ROC last 12 Months | -23.78 | |||
Return on invested Capital Q | -3.58 | |||
Return on invested Capital Y | -9.82 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.40 | ||||
| 0.39 | ||||
| - | ||||
| - | ||||
| -22.40 | ||||
| -0.50 | ||||
| -11.85 | ||||
| 3.05 | ||||
| 58.65M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.50 | ||||
| 1.60 | ||||
| 0.01 | ||||
| 0.05 | ||||
| -106.90 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | - | -0.12 | - |
| Q03 2020 | - | -0.03 | - |
| Q01 2020 | - | -0.09 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.30M |
| Shares Outstanding | 58.28K |
| Shares Float | 27.81M |
| Trades Count | 8.85K |
| Dollar Volume | 1.37M |
| Avg. Volume | 199.71K |
| Avg. Weekly Volume | 137.49K |
| Avg. Monthly Volume | 267.48K |
| Avg. Quarterly Volume | 194.16K |
Enochian Biosciences Inc. (NASDAQ: ENOB) stock closed at 0.7 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 88.13K shares and market capitalization of 46.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Enochian Biosciences Inc. CEO is Mark R. Dybul.
The one-year performance of Enochian Biosciences Inc. stock is -75.52%, while year-to-date (YTD) performance is -22.65%. ENOB stock has a five-year performance of -89.72%. Its 52-week range is between 0.3928 and 2.99, which gives ENOB stock a 52-week price range ratio of %
Enochian Biosciences Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.39, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -23.57%, a ROC of -23.78% and a ROE of -25.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Enochian Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enochian Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Enochian Biosciences Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enochian Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enochian Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enochian Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.48, ATR14 : 0.08, CCI20 : 170.75, Chaikin Money Flow : 0.44, MACD : 0.02, Money Flow Index : 75.77, ROC : 15.00, RSI : 59.96, STOCH (14,3) : 75.72, STOCH RSI : 1.00, UO : 43.72, Williams %R : -24.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enochian Biosciences Inc. in the last 12-months were:
Enochian Biosciences Inc.
Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in identifying, developing, manufacturing, and commercializing gene therapies. The company develops cures and providing prevention for infectious diseases and cancer. It is also engaged in developing HIV preventative vaccine and cures and Cellular immune-oncology products.
CEO: Mark R. Dybul
Telephone: +1 786 888-1685
Address: 2080 Century Park East, Los Angeles 90067-2012, CA, US
Number of employees: 10
